← Leaderboards
Christopher D Huston
University Of Vermont & St Agric College
$6,704,821
Attributed
$10,111,452
Total exposure
15
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,714,913 · 16
By mechanism
R01$4,892,724 · 2
P20$4,120,609 · 8
R21$1,709,549 · 4
R33$1,343,491 · 1
K08$648,540 · 1
Top collaborators
- Marvin J Meyers10 shared
- David Griggs5 shared
- Francis Michael Sverdrup5 shared
- Beth Diane Kirkpatrick1 shared
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Francis Michael Sverdrup$1,163,110
Others in their field
Top investigators on “Parasites”
- Stephen Lev Hoffman · Sanaria, Inc.$58,168,134
- L David Sibley · Washington University$47,818,729
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Wilhelmus G. J. Hol · University Of Washington$32,390,237
- Philip Jon Rosenthal · University Of California San Francisco$31,794,731
- Daniel F. Hoft · Saint Louis University$31,137,771
Research focus
ParasitesInfectionDiarrheaCellsBaseIn VitroBiologyIn VivoProteinsIntestinesNitazoxanideEntamoeba HistolyticaCryptosporidiumImmunocompromised HostUnited StatesPhagocytosisAcquired Immunodeficiency SyndromeDrug DevelopmentPharmaceutical PreparationsCryptosporidium ParvumChildCryptosporidiosisPlacebosWaterborne
Grant awards (35)
Methods to study Cryptosporidium drug resistance$234,000
R21 · FY2024 · AI · contact PI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$699,764
R01 · FY2023 · AI · contact PI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$447,404
R33 · FY2023 · AI · contact PI
Methods to study Cryptosporidium drug resistance$195,000
R21 · FY2023 · AI · contact PI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$697,491
R01 · FY2022 · AI · contact PI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$441,321
R33 · FY2022 · AI · contact PI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$620,271
R01 · FY2021 · AI · contact PI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$454,766
R33 · FY2021 · AI · contact PI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$620,271
R01 · FY2020 · AI · contact PI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$230,252
R21 · FY2020 · AI · contact PI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$691,919
R01 · FY2019 · AI · contact PI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$206,487
R21 · FY2019 · AI · contact PI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$2,603,461
P20 · FY2018 · GM
Alteration and Renovation for the Kirkpatrick/Huston COBRE$300,001
P20 · FY2018 · GM · contact PI
Continuous in vitro culture and treatment of Cryptosporidium using small molecule differentiation inhibitors$230,372
R21 · FY2018 · AI · contact PI
Continuous in vitro culture and treatment of Cryptosporidium using small molecule differentiation inhibitors$194,063
R21 · FY2017 · AI · contact PI
Novel approaches to develop a treatment for cryptosporidiosis$228,750
R21 · FY2014 · AI · contact PI
Novel approaches to develop a treatment for cryptosporidiosis$190,625
R21 · FY2013 · AI · contact PI
Molecular Mechanism of Entamoeba histolytica phagocytosis$295,010
R01 · FY2012 · AI · contact PI
Molecular Mechanism of Entamoeba histolytica phagocytosis$295,010
R01 · FY2011 · AI · contact PI
VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS$177,049
P20 · FY2011 · RR · contact PI
Molecular Mechanism of Entamoeba histolytica phagocytosis$297,990
R01 · FY2010 · AI · contact PI
VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS$168,613
P20 · FY2010 · RR · contact PI
Molecular Mechanism of Entamoeba histolytica phagocytosis$301,000
R01 · FY2009 · AI · contact PI
VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS$166,446
P20 · FY2009 · RR · contact PI
Molecular Mechanism of Entamoeba histolytica phagocytosis$99,450
R01 · FY2009 · AI · contact PI
Molecular Mechanism of Entamoeba histolytica phagocytosis$274,548
R01 · FY2008 · AI · contact PI
VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS$175,412
P20 · FY2008 · RR · contact PI
VERMONT COBRE: MOLECULAR MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS$202,339
P20 · FY2007 · RR · contact PI
E. histolytica phagocytosis of apoptotic host cells$134,028
K08 · FY2007 · AI · contact PI
VERMONT COBRE: MOLECULAR MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS$327,288
P20 · FY2006 · RR · contact PI
E. histolytica phagocytosis of apoptotic host cells$134,028
K08 · FY2006 · AI · contact PI
E. histolytica phagocytosis of apoptotic host cells$134,028
K08 · FY2005 · AI
E. histolytica phagocytosis of apoptotic host cells$123,228
K08 · FY2004 · AI
E histolytica phagocytosis of apoptotic host cells$123,228
K08 · FY2003 · AI